Solvonis Therapeutics plc Revenue
Biotechnology Research • 
Eccleston Place, London, United Kingdom • 1-10 Employees
Solvonis Therapeutics plc revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Key Contact at Solvonis Therapeutics plc
Renata Crome
Non Executive Director
Company overview
| Headquarters | Eccleston Place, London, England SW1W 9NF, GB |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Addiction, Neuroscience, Mental Health, Ptsd, CNS, AUD |
| Employees | 1-10 |
| Socials |
Solvonis Therapeutics plc Email Formats
Solvonis Therapeutics plc uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@solvonis.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@solvonis.com | 100% |
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing innovative medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange main market, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need. The company’s current focus is on Alcohol Use Disorder (AUD)—affecting over 40 million people across the U.S., UK, and EU4—and Post-Traumatic Stress Disorder (PTSD), which impacts more than 13 million adults in the U.S. and approximately 20 million across the same regions.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Solvonis Therapeutics plc has never raised funding before.
Italy
United States
Netherlands
CzechiaFrequently asked questions
4.8
40,000 users
